ProfileGDS5678 / 1451784_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% 99% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 111.446699
GSM967853U87-EV human glioblastoma xenograft - Control 211.51599
GSM967854U87-EV human glioblastoma xenograft - Control 311.416599
GSM967855U87-EV human glioblastoma xenograft - Control 413.542499
GSM967856U87-EV human glioblastoma xenograft - Control 512.036399
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 111.697399
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 211.6999
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 311.858999
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 412.032599
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 111.686599
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 211.482699
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 312.242299
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 411.610999
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 511.317399